Welcome to Medpharm Publications

Medpharm Publications was founded in 1988 and has established itself as the largest medical and pharmaceutical journal publisher in South Africa.

With a publications list of more than ten titles comprising of over fifty journal editions, Medpharm Publications reach more than 40 000 healthcare workers countrywide with printed editions, and has established a global audience with the online editions.

The majority of Medpharm Publications’ journals are associated with professional or scholarly societies and acts as the official South African mouthpiece in the associated discipline. All journals are web-based, most of which are fully peer-reviewed, with five titles accredited by the South African Department of Higher Education and Training (DHET) to earn research subsidies for academic departments.

As a publisher, passionate about journal publishing, we believe that South African researchers and clinicians can and will make a significant contribution to world medical literature.

ConvaCare Clinics to open its first South African clinic to meet growing professional wound care demand

ConvaCare Clinics opened its first wound and stoma clinic as its first expansion into South Africa, meeting the increasing demand for professional wound and stoma care

Women leading  the charge in the fight against malaria 

Over 7 million lives have been saved since 2000, largely thanks to the women who work on the frontlines to prevent, diagnose and treat malaria.

Launch of TRACTINFECT 3 g powder

Aspen is proud to announce the launch of TRACTINFECT and its addition to Aspen’s Urology portfolio

Dupixent® (dupilumab) now available in South Africa for treatment of adult patients with moderate-to-severe atopic dermatitis

Sanofi has announced that Dupixent® (dupilumab) is now available in South Africa. Dupixent® is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical corticosteroid therapies, or when those therapies are not advisable

Setting our sights on ILEVRO 0.3% once daily

Novartis Ophthalmology are proud to announce the launch of new ILEVRO® Eye Drops, (nepafenac 3 mg/ml, suspension), a prodrug NSAID at a convenient and compliance enhancing once-daily dose

For all official information and updates regarding COVID-19, please visit the South African Department of Health’s website